Download PDF
Semin Liver Dis 2002; 22(2): 169-184
DOI: 10.1055/s-2002-30102
Copyright © 2002 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Hepatotoxicity of Commonly Used Drugs: Nonsteroidal Anti-Inflammatory Drugs, Antihypertensives, Antidiabetic Agents, Anticonvulsants, Lipid-Lowering Agents, Psychotropic Drugs

Shivakumar Chitturi, Jacob George
  • Storr Liver Unit, Westmead Millennium Institute, University of Sydney at Westmead Hospital, Westmead, NSW, Australia
Further Information

Publication History

Publication Date:
16 May 2002 (online)

    Permissions and Reprints

ABSTRACT

Hepatotoxic adverse drug reactions have contributed to the decline of many promising therapies, even among mainstream medication classes (bromfenac and troglitazone are recent examples). The spectrum of nonsteroidal anti-inflammatory drug-related liver toxicity continues to expand, with reports in children, interactive toxicity in persons with hepatitis C, and recognition of the toxicity of both the preferential and selective cyclooxygenase-2 inhibitors. Of the antihypertensive agents, methyldopa is now rarely prescribed and adverse effects are reported infrequently, whereas cases of liver injury associated with the angiotensin receptor and converting enzyme inhibitors are increasingly reported. Of the antidiabetic agents, acarbose, gliclazide, metformin, and human insulin have been implicated in causing liver injury. To date, the newer thiazolidinediones do not appear to share the hepatotoxic potential of troglitazone, although a few reports of acute hepatitis have accrued. Although liver injury has been associated with the ``statins,'' the frequency of such toxicity is lower than that of the background population and the value of biochemical monitoring remains unproved. Newer concepts in anticonvulsant hepatotoxicity have been the recognition of the reactive metabolite syndrome, delineation of the risk factors for valproic acid toxicity, the potential role of carnitine in preventing valproic acid hepatotoxicity, and the toxicity of second-line antiepileptic drugs. Liver injury associated with newer psychotropic agents, particularly the selective serotonin reuptake inhibitors, is also discussed. The focus of the review is the hepatotoxicity of commonly used drugs with particular reference to recent and novel reports of toxicity. Well-known causes of liver injury such as chlorpromazine, phenytoin, and methyldopa are not discussed.

KEYWORDS

Hepatotoxicity - drug-induced liver disease - liver injury - cholestasis - fulminant hepatic failure - antihypertensive drugs - antidiabetic agents - nonsteroidal anti-inflammatory drugs - psychotropic agents

REFERENCES

  • 1 Friis H, Andreasen P B. Drug-induced hepatic injury: an analysis of 1100 case reports to the Danish Committee on Adverse Drug Reactions between 1978 and 1987.  J Intern Med . 1992;  232 133-138
    PubMedGoogle Scholar
  • 2 Fontana R J, McCashland T M, Benner K G. Acute liver failure associated with prolonged use of bromfenac leading to liver transplantation. The Acute Liver Failure Study Group.  Liver Transpl Surg . 1999;  5 480-484
    CrossrefPubMedGoogle Scholar
  • 3 Garcia Rodriguez A L, Williams R, Derby L E. Acute liver injury associated with nonsteroidal anti-inflammatory drugs and the role of risk factors.  Arch Intern Med . 1994;  154 311-316
    CrossrefPubMedGoogle Scholar
  • 4 Garcia Rodriguez A L, Perez Gutthann S, Walker A M, Lueck L. The role of non-steroidal anti-inflammatory drugs in acute liver injury.  BMJ . 1992;  305 865-868
    PubMedGoogle Scholar
  • 5 Hernandez-Diaz S, Garcia-Rodriguez L A. Epidemiologic assessment of the safety of conventional nonsteroidal anti-inflammatory drugs.  Am J Med . 2001;  110(Suppl 3A) 20S-27S
    CrossrefPubMedGoogle Scholar
  • 6 Laffi G, La Villa G, Pinzani M. Arachidonic acid derivatives and renal function in liver cirrhosis.  Semin Nephrol . 1997;  17 530-548
    PubMedGoogle Scholar
  • 7 De Ledinghen V, Heresbach D, Fourdan O. Anti-inflammatory drugs and variceal bleeding: a case-control study.  Gut . 1999;  44 270-273
    PubMedGoogle Scholar
  • 8 Autret-Leca E, Jonville-Bera A P, Llau M E. Incidence of Reye's syndrome in France: a hospital-based survey.  J Clin Epidemiol . 2001;  54 857-862
    CrossrefPubMedGoogle Scholar
  • 9 Belay E D, Bresee J S, Holman R C. Reye's syndrome in the United States from 1981 through 1997.  N Engl J Med . 1999;  340 1377-1382
    CrossrefPubMedGoogle Scholar
  • 10 Buttar N S, Wang K K. The ``aspirin'' of the new millennium: cyclooxygenase-2 inhibitors.  Mayo Clin Proc . 2000;  75 1027-1038
    PubMedGoogle Scholar
  • 11 Maddrey W C, Maurath C J, Verburg K M, Geis G S. The hepatic safety of and tolerability of the novel cyclooxygenase-2 inhibitor celecoxib.  Am J Ther . 2000;  7 153-158
    PubMedGoogle Scholar
  • 12 O'Beirne J P, Cairns S R. Drug points: cholestatic hepatitis in association with celecoxib (letter).  BMJ . 2001;  323 23
    CrossrefPubMedGoogle Scholar
  • 13 Galan M V, Gordon S C, Silverman A L. Celecoxib-induced cholestatic hepatitis (letter).  Ann Intern Med . 2001;  134 254
    PubMedGoogle Scholar
  • 14 Carrillo-Jimenez R, Nurnberger M. Celecoxib-induced acute pancreatitis and hepatitis.  Arch Intern Med . 2000;  170 553-554
    PubMedGoogle Scholar
  • 15 Jones D B. COX-2 inhibitors (letter).  Med J Aust . 2001;  174 368
    PubMedGoogle Scholar
  • 16 Nachimuthu S, Volfinzon L, Gopal L. Acute hepatocellular and cholestatic injury in a patient taking celecoxib.  Postgrad Med J . 2001;  77 548-550
    CrossrefPubMedGoogle Scholar
  • 17 Knowles S, Shapiro L, Shear N H. Should celecoxib be contraindicated in patients who are allergic to sulfonamides?.  <~>Revisiting the meaning of `sulfa' allergy. Drug Saf . 2001;  24 239-247
    PubMedGoogle Scholar
  • 18 Tilles S A. Practical issues in the management of hypersensitivity reactions: sulfonamides.  South Med J . 2001;  94 817-824
    PubMedGoogle Scholar
  • 19 Van Steenbergen W, Peeters P, De Bondt J. Nimesulide-induced acute hepatitis: evidence from six cases.  J Hepatol . 1998;  29 135-141
    CrossrefPubMedGoogle Scholar
  • 20 Schattner A, Sokolovskaya N, Cohen J. Fatal hepatitis and renal failure during treatment with nimesulide.  J Intern Med . 2000;  247 153-155
    CrossrefPubMedGoogle Scholar
  • 21 Andrade R J, Lucena M I, Fernandez M C, Gonzalez M. Fatal hepatitis associated with nimesulide.  J Hepatol . 2000;  32 174
    PubMedGoogle Scholar
  • 22 Weiss P, Mouallem M, Bruck R. Nimesulide-induced hepatitis and acute liver failure.  Isr Med Assoc J . 1999;  1 89-91
    PubMedGoogle Scholar
  • 23 McCormick P A, Kennedy F, Curry M, Traynor O. COX-2 inhibitor and fulminant hepatic failure (letter).  Lancet . 1999;  353 40-41
    PubMedGoogle Scholar
  • 24 Staerkel P, Horsmans Y. Meloxicam-induced liver toxicity.  Acta Gastroenterol Belg . 1999;  62 255-256
    PubMedGoogle Scholar
  • 25 Mabee C L, Mabee S W, Baker P B. Fulminant hepatic failure associated with etodolac use.  Am J Gastroenterol . 1995;  90 659-661
    PubMedGoogle Scholar
  • 26 Stempel D A, Miller 3rd J J. Lymphopenia and hepatic toxicity with ibuprofen.  J Pediatr . 1977;  90 657-658
    PubMedGoogle Scholar
  • 27 Alam I, Ferrell L D, Bass N M. Vanishing bile duct syndrome temporally associated with ibuprofen use.  Am J Gastroenterol . 1996;  91 1626-1630
    PubMedGoogle Scholar
  • 28 Laurent S, Rahier J, Geubel A P. Subfulminant hepatitis requiring liver transplantation following ibuprofen overdose.  Liver . 2000;  20 93-94
    PubMedGoogle Scholar
  • 29 Srivastava M, Perez-Atayde A, Jonas M M. Drug-associated acute-onset vanishing bile duct and Stevens-Johnson syndromes in a child.  Gastroenterology . 1998;  115 743-746
    PubMedGoogle Scholar
  • 30 Sternlieb P, Robinson R M. Stevens-Johnson syndrome plus toxic hepatitis due to ibuprofen.  NY State J Med . 1978;  78 1239-1243
    PubMedGoogle Scholar
  • 31 Riley 3rd R T, Smith J P. Ibuprofen-induced hepatotoxicity in patients with chronic hepatitis C: a case series.  Am J Gastroenterol . 1998;  93 1563-1565
    PubMedGoogle Scholar
  • 32 Guldenschuh I, Hurlimann R, Muller A. Relationship between APC genotype, polyp distribution, and oral sulindac treatment in the colon and rectum of patients with familial adenomatous polyposis.  Dis Colon Rectum . 2001;  44 1090-1097
    PubMedGoogle Scholar
  • 33 Tarazi E M, Harter J G, Zimmerman H J. Sulindac-associated hepatic injury: analysis of 91 cases reported to the Food and Drug Administration.  Gastroenterology . 1993;  104 569-574
    PubMedGoogle Scholar
  • 34 Lerche A, Vyberg M, Kirkegaard E. Acute cholangitis and pancreatitis associated with sulindac (Clinoril).  Histopathology . 1987;  11 647-653
    PubMedGoogle Scholar
  • 35 Bolder U, Trang N V, Hagey L R. Sulindac is excreted into bile by a canalicular bile salt pump and undergoes a cholehepatic circulation in rats.  Gastroenterology . 1999;  117 962-971
    PubMedGoogle Scholar
  • 36 Helfgott S M, Sandberg-Cook J, Zakim D, Nestler J. Diclofenac-associated hepatotoxicity.  JAMA . 1990;  264 2660-2662
    CrossrefPubMedGoogle Scholar
  • 37 Iveson T J, Ryley N G, Kelly P MA. Diclofenac associated hepatitis.  J Hepatol . 1990;  10 85-89
    PubMedGoogle Scholar
  • 38 Breen E G, McNicholl J, Cosgrove E. Fatal hepatitis associated with diclofenac.  Gut . 1986;  27 1390-1393
    PubMedGoogle Scholar
  • 39 Banks A T, Zimmerman H J, Ishak K G, Harter J G. Diclofenac-associated hepatotoxicity: analysis of 180 cases reported to the Food and Drug Administration as adverse reactions.  Hepatology . 1995;  22 820-827
    CrossrefPubMedGoogle Scholar
  • 40 Scully L J, Clarke D, Barr R J. Diclofenac induced hepatitis. 3 cases with features of autoimmune chronic active hepatitis.  Dig Dis Sci . 1993;  38 744-751
    CrossrefPubMedGoogle Scholar
  • 41 Greaves R R, Agarwal A, Patch D. Inadvertent diclofenac rechallenge from generic and non-generic prescribing, leading to liver transplantation for fulminant liver failure.  Eur J Gastroenterol Hepatol . 2001;  13 71-73
    CrossrefPubMedGoogle Scholar
  • 42 Aithal G P, Day C P, Leathart J B, Daly A K. Relationship of polymorphism in CYP2C9 to genetic susceptibility to diclofenac-induced hepatitis.  Pharmacogenetics . 2000;  10 511-518
    CrossrefPubMedGoogle Scholar
  • 43 Bort R, Ponsoda X, Jover R. Diclofenac toxicity to hepatocytes: a role for drug metabolism in cell toxicity.  J Pharmacol Exp Ther . 1999;  288 65-72
    PubMedGoogle Scholar
  • 44 Zimmerman H J. Effects of aspirin and acetaminophen on the liver.  Arch Intern Med . 1981;  141 333-342
    CrossrefPubMedGoogle Scholar
  • 45 Cappell M S, Kozicky O, Competiello L S. Indomethacin-associated cholestasis.  J Clin Gastroenterol . 1988;  10 445-447
    PubMedGoogle Scholar
  • 46 Victorino R M, Silveira J C, Baptista A, de Moura C M. Jaundice associated with naproxen.  Postgrad Med J . 1980;  56 368-370
    PubMedGoogle Scholar
  • 47 Kethu S R, Rukkannagari S, Lansford C L. Oxaprozin-induced symptomatic hepatotoxicity.  Ann Pharmacother . 1999;  33 942-944
    PubMedGoogle Scholar
  • 48 Purdum 3rd P P, Shelden S L, Boyd J W, Shiffman M L. Oxaprozin-induced fulminant hepatitis.  Ann Pharmacother . 1994;  28 1159-1161
    PubMedGoogle Scholar
  • 49 Paterson D, Kerlin P, Walker N. Piroxicam induced submassive necrosis of the liver.  Gut . 1992;  33 1436-1438
    CrossrefPubMedGoogle Scholar
  • 50 Sherman K E, Jones C. Hepatotoxicity associated with piroxicam use.  Gastroenterology . 1992;  103 354-355
    PubMedGoogle Scholar
  • 51 Katsinelos P, Katsos I, Patsiaoura K. Tenoxicam-associated hepatic injury: a case report and review.  Eur J Gastroenterol Hepatol . 1997;  9 403-406
    PubMedGoogle Scholar
  • 52 Garcia-Rodriguez L A, Cattaruzzi C, Grazia Troncon M. Acute liver injury and droxicam use in the region of Friuli-Venezia Giulia.  Br J Clin Pharmacol . 1995;  40 104-105
    PubMedGoogle Scholar
  • 53 Cohen S, Cannon G W, Schiff M. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of leflunomide in the treatment of rheumatoid arthritis trial investigator group.  Arthritis Rheum . 2001;  44 1984-1992
    CrossrefPubMedGoogle Scholar
  • 54 Weinblatt M E, Dixon J A, Falchuk K R. Serious liver disease in a patient receiving methotrexate and leflunomide.  Arthritis Rheum . 2000;  43 2609-2611
    CrossrefPubMedGoogle Scholar
  • 55 Targan S R, Hanauer S B, van Deventer J H S. Crohn's Disease cA2 Study Group. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor-alpha for Crohn's disease.  N Engl J Med . 1997;  337 1029-1035
    CrossrefPubMedGoogle Scholar
  • 56 Hanauer S B. Review article: safety of infliximab in clinical trials.  Aliment Pharmacol Ther . 1999;  13(Suppl 4) 16-22
    PubMedGoogle Scholar
  • 57 Menghini V V, Arora A S. Infliximab-associated reversible cholestatic liver disease.  Mayo Clin Proc . 2001;  76 84-86
    PubMedGoogle Scholar
  • 58 Saleem G, Li S C, MacPherson B R. Hepatitis with interface inflammation and IgG, IgM, and IgA anti-double-stranded DNA antibodies following infliximab therapy.  Arthritis Rheum . 2001;  44 1966-1968
    CrossrefPubMedGoogle Scholar
  • 59 Reinus J F, Persky S, Burkiewicz J S. Severe liver injury after treatment with the leukotriene receptor antagonist zafirlukast.  Ann Intern Med . 2000;  133 964-968
    PubMedGoogle Scholar
  • 60 Torres M, Reddy K R. Severe liver injury (letter).  Ann Intern Med . 2001;  135 550
    PubMedGoogle Scholar
  • 61 Moles J R, Primo J, Fernandez J M, Hinojosa J E. Acute hepatocellular injury associated with zafirlukast (letter).  J Hepatol . 2001;  35 541-542
    CrossrefPubMedGoogle Scholar
  • 62 Actis G C, Morgando A, Lagget M. Zafirlukast-related hepatitis: report of a further case (letter).  J Hepatol . 2001;  35 539-541
    CrossrefPubMedGoogle Scholar
  • 63 Maddrey W C, Boitnott J K. Severe hepatitis from methyldopa.  Gastroenterology . 1975;  68 351-360
    PubMedGoogle Scholar
  • 64 Tanner L A, Bosco L A, Zimmerman H J. Hepatic injury after acebutalol.  Ann Intern Med . 1989;  111 533-534
    PubMedGoogle Scholar
  • 65 Larrey D, Henrion J, Heller F. Metoprolol-induced hepatitis: rechallenge and drug oxidation phenotyping.  Ann Intern Med . 1988;  108 67-68
    PubMedGoogle Scholar
  • 66 Schwartz M S. Atenolol-associated cholestasis.  Am J Gastroenterol . 1989;  184 1084-1086
    PubMedGoogle Scholar
  • 67 Yusuf S W, Mishra R M. Hepatic dysfunction associated with atenolol.  Lancet . 1995;  346 192
    PubMedGoogle Scholar
  • 68 Clark J, Zimmerman H J, Tanner L. Labetalol hepatotoxicity.  Ann Intern Med . 1990;  113 210-213
    PubMedGoogle Scholar
  • 69 Kumar K L, Colley C A. Verapamil-induced hepatotoxicity.  West J Med . 1994;  160 485-486
    PubMedGoogle Scholar
  • 70 Toft E, Vyberg M, Therkelsen K. Diltiazem-induced granulomatous hepatitis.  Histopathology . 1991;  18 474-475
    PubMedGoogle Scholar
  • 71 Babany G, Uzzan F, Larrey D. Alcoholic-like liver lesions induced by nifedipine.  Hepatology . 1989;  9 252-255
    PubMedGoogle Scholar
  • 72 Nunes A C, Amaro P, Mac as F. Fosinopril-induced prolonged cholestatic jaundice and pruritus: first case report.  Eur J Gastroenterol Hepatol . 2001;  13 279-282
    CrossrefPubMedGoogle Scholar
  • 73 Rahmat J, Gelfand R L, Gelfand M. Captopril-associated cholestatic jaundice.  Ann Intern Med . 1985;  102 56-58
    PubMedGoogle Scholar
  • 74 Rosellini S R, Costa P L, Gaudio M. Hepatic injury related to enalapril.  Gastroenterology . 1989;  97 810
    PubMedGoogle Scholar
  • 75 Todd P, Levison D, Farthing M JG. Enalapril-related cholestatic jaundice.  J R Soc Med . 1990;  83 271-272
    PubMedGoogle Scholar
  • 76 Hagley M T, Hulisz D T, Burns C M. Hepatotoxicity associated with angiotensin-converting enzyme inhibitors.  Ann Pharmacother . 1993;  27 228-231
    PubMedGoogle Scholar
  • 77 Jeserich M, Ihling C, Allgaier H P. Acute liver failure due to enalapril.  Herz . 2000;  25 689-693
    PubMedGoogle Scholar
  • 78 Larrey D, Babany G, Bernuau J. Fulminant hepatitis after lisinopril administration.  Gastroenterology . 1990;  99 1832-1833
    PubMedGoogle Scholar
  • 79 Hagley M T, Benak R L, Hulisz D T. Suspected cross-reactivity of enalapril- and captopril-induced hepatotoxicity.  Ann Pharmacother . 1992;  26 780-781
    PubMedGoogle Scholar
  • 80 Hariraj R, Stoner E, Jader S, Preston D M. Drug points: prolonged cholestasis associated with irbesartan.  BMJ . 2000;  321 547
    CrossrefPubMedGoogle Scholar
  • 81 See S, Stirling A L. Candesartan cilexetil: an angiotensin II-receptor blocker.  Am J Health Syst Pharm . 2000;  57 739-746
    PubMedGoogle Scholar
  • 82 Vallejo I, Garcia Morillo S, Pamies E. Acute hepatitis induced by candesartan.  Med Clin (Barc) . 2000;  115 719
    PubMedGoogle Scholar
  • 83 Gonzalez-Jimenez D, Varela J M, Calderon E. Candesartan and acute liver injury.  Eur J Clin Pharmacol . 2000;  56 769-770
    CrossrefPubMedGoogle Scholar
  • 84 Andrade R J, Lucena M I, Santalla F. Hepatic injury associated with losartan.  Ann Pharmacother. 1998;  32 1371
    PubMedGoogle Scholar
  • 85 Gonzalez-Abraldes J, Albillos A, Banares R. Randomized comparison of long-term losartan versus propranolol in lowering portal pressure in cirrhosis.  Gastroenterology . 2001;  121 382-388
    PubMedGoogle Scholar
  • 86 Schneider A W, Kalk J F, Klein C P. Effect of losartan, an angiotensin II receptor antagonist, on portal pressure in cirrhosis.  Hepatology . 1999;  29 334-339
    CrossrefPubMedGoogle Scholar
  • 87 Nygaard B, Strandgaard S. Marked hepatotoxicity associated with losartan treatment.  Blood Press . 1996;  5 190-191
    PubMedGoogle Scholar
  • 88 Thai K E, Sinclair R D. Spironolactone-induced hepatitis.  Australas J Dermatol . 2001;  42 180-182
    CrossrefPubMedGoogle Scholar
  • 89 Renkes P, Gaucher P, Trechot P. Spironolactone and hepatic toxicity.  JAMA . 1995;  273 376-377
    CrossrefPubMedGoogle Scholar
  • 90 Shuck J, Shen S, Owensby L. Spironolactone hepatitis in primary hyperaldosteronism.  Ann Intern Med . 1981;  95 708-710
    PubMedGoogle Scholar
  • 91 Cetin M, Demirci D, Unal A. Frequency of flutamide induced hepatotoxicity in patients with prostate carcinoma.  Hum Exp Toxicol . 1999;  18 137-140
    CrossrefPubMedGoogle Scholar
  • 92 Andrade R J, Lucena M I, Fernandez M C. Fulminant liver failure associated with flutamide therapy for hirsutism (letter).  Lancet . 1999;  33 983
    PubMedGoogle Scholar
  • 93 Jick S S, Stender M, Myers M W. Frequency of liver disease in type 2 diabetic patients treated with oral antidiabetic agents.  Diabetes Care . 2000;  22 2067-2071
    PubMedGoogle Scholar
  • 94 Schneider H L, Hornbach K D, Kniaz J L, Efrusy M E. Chlorpropamide hepatotoxicity: report of a case and review of the literature.  Am J Gastroenterol . 1984;  79 721-724
    PubMedGoogle Scholar
  • 95 Goodman R C, Dean P J, Radparvar A, Kitabchi A E. Glyburide-induced hepatitis.  Ann Intern Med . 1987;  106 837-839
    PubMedGoogle Scholar
  • 96 Wongpaitoon V, Russell R F, Mills P R, Patrick R S. Intrahepatic cholestasis and cutaneous bullae associated with glibenclamide therapy.  Postgrad Med . 1981;  57 244-246
    PubMedGoogle Scholar
  • 97 Saw D, Pitman E, Maung M. Granulomatous hepatitis associated with glyburide.  Dig Dis Sci . 1996;  41 322-325
    PubMedGoogle Scholar
  • 98 Gregory D H, Zaki G F, Sarosi G A, Carey Jr B J. Chronic cholestasis following prolonged tolbutamide administration.  Arch Pathol . 1967;  84 194
    PubMedGoogle Scholar
  • 99 Van Thiel H D, de Belle R, Mellow M. Tolazamide hepatotoxicity.  Gastroenterology . 1974;  67 506-510
    PubMedGoogle Scholar
  • 100 Nakao N L, Gelb A M, Stenger R, Sitgel J H. A case of chronic liver disease due to tolazamide.  Gastroenterology . 1985;  89 192-195
    PubMedGoogle Scholar
  • 101 Chitturi S, Le V, Kench J. Gliclazide-induced acute hepatitis with hypersensitivity features (in press).  Dig Dis Sci.
    PubMedGoogle Scholar
  • 102 Dourakis S P, Tzemanakis E, Sinani C. Gliclazide-induced acute hepatitis.  Eur J Gastroenterol Hepatol . 2000;  12 119-121
    PubMedGoogle Scholar
  • 103 Sitruk V, Mohib S, Grando-Lemaire V. Acute cholestatic hepatitis induced by glimepiride.  Gastroenterol Clin Biol . 2000;  24 1233-1234
    PubMedGoogle Scholar
  • 104 Clarke B F, Campbell J W, Ewing D J. Generalized hypersensitivity reaction and visceral arteritis with fatal outcome during glibenclamide therapy.  Diabetes . 1974;  23 739-742
    PubMedGoogle Scholar
  • 105 Van Basten P J, Van Hoek B, Zeijen R, Stockbrugger R. Glyburide-induced cholestatic hepatitis and liver failure. Case report and review of the literature.  Neth J Med . 1992;  40 305-307
    PubMedGoogle Scholar
  • 106 Babich M M, Pike I, Shiffman M L. Metformin-induced acute hepatitis.  Am J Med . 1998;  104 490-492
    CrossrefPubMedGoogle Scholar
  • 107 Desilets D J, Shorr A F, Moran K A, Holtzmuller K C. Cholestatic jaundice associated with the use of metformin.  Am J Gastroenterol . 2001;  96 2257-2258
    CrossrefPubMedGoogle Scholar
  • 108 Harrigan R A, Nathan M S, Beattie P. Oral agents for the treatment of type 2 diabetes mellitus: pharmacology, toxicity, and treatment.  Ann Emerg Med . 2001;  38 68-78
    PubMedGoogle Scholar
  • 109 Andrade R J, Lucena M, Vega J L. Acarbose-associated hepatotoxicity (letter).  Diabetes Care . 1998;  21 2029-2030
    PubMedGoogle Scholar
  • 110 Carrascosa M, Pascual F, Aresti S. Acarbose-induced acute severe hepatotoxicity (letter).  Lancet . 1997;  349 698-699
    PubMedGoogle Scholar
  • 111 Fujimoto Y, Ohhira M, Miyokawa N. Acarbose-induced hepatic injury (letter).  Lancet . 1998;  351 340
    PubMedGoogle Scholar
  • 112 Masumoto T, Ishikawa M, Yamauchi Y. Drug-induced hepatitis with severe cholestasis due to voglibose.  Int Hepatol Commun . 1996;  5 289-296
    PubMedGoogle Scholar
  • 113 Scott L J, Spencer C M. Miglitol: a review of its therapeutic potential in type 2 diabetes mellitus.  Drugs . 2000;  59 512-549
    PubMedGoogle Scholar
  • 114 Vella A, de Groen C P, Dinneen S F. Fatal hepatotoxicity associated with troglitazone (letter).  Ann Intern Med . 1998;  129 1080
    PubMedGoogle Scholar
  • 115 Murphy E J, Davern T J, Shakil O. Troglitazone-induced fulminant hepatic failure.  Dig Dis Sci . 2000;  45 549-553
    CrossrefPubMedGoogle Scholar
  • 116 Schiano T, Dolehide K, Hart J, Baker A L. Severe but reversible hepatitis induced by troglitazone.  Dig Dis Sci . 2000;  45 1039-1042
    CrossrefPubMedGoogle Scholar
  • 117 Gitlin N, Julie N L, Spurr C L. Two cases of severe clinical and histologic hepatotoxicity associated with troglitazone.  Ann Intern Med . 1998;  129 36-38
    CrossrefPubMedGoogle Scholar
  • 118 Neuschwander-Tetri B A, Isley W L, Oki J C. Troglitazone-induced hepatic failure leading to liver transplantation.  Ann Intern Med . 1998;  129 38-41
    PubMedGoogle Scholar
  • 119 Malik A H, Prasad P, Saboorian M H. Hepatic injury due to troglitazone.  Dig Dis Sci . 2000;  45 210-214
    CrossrefPubMedGoogle Scholar
  • 120 Bloomgarden Z T. American Diabetes Association 60th Scientific Sessions, 2000; thiazolidinediones, obesity, and related topics.  Diabetes Care . 2001;  24 162-166
    PubMedGoogle Scholar
  • 121 Kohlroser J, Mathai J, Reichheld J. Hepatotoxicity due to troglitazone: report of two cases and review of adverse events reported to the United States Food and Drug Administration.  Am J Gastroenterol . 2000;  95 272-276
    CrossrefPubMedGoogle Scholar
  • 122 Watkins P B, Whitcomb R W. Hepatic dysfunction associated with troglitazone (letter).  N Engl J Med . 1998;  338 916-917
    CrossrefPubMedGoogle Scholar
  • 123 Caldwell S H, Hespenheide E E, von Borstel W R. Myositis, microvesicular hepatitis, and progression to cirrhosis from troglitazone added to simvastatin.  Dig Dis Sci . 2001;  46 376-378
    CrossrefPubMedGoogle Scholar
  • 124 Bell D SH, Ovalle F. Late-onset troglitazone-induced hepatic dysfunction (letter).  Diabetes Care . 2000;  23 128-129
    PubMedGoogle Scholar
  • 125 Iwase M, Yamaguchi M, Yoshinari M. A Japanese case of liver dysfunction after 19 months of troglitazone treatment.  Diabetes Care . 1999;  22 1382-1384
    PubMedGoogle Scholar
  • 126 Jagannath S, Rai R. Rapid-onset subfulminant liver failure associated with troglitazone.  Ann Intern Med . 2000;  132 677
    PubMedGoogle Scholar
  • 127 Menon K VN, Angulo P, Lindor K D. Severe cholestatic hepatitis from troglitazone in a patient with nonalcoholic steatohepatitis and diabetes mellitus.  Am J Gastroenterol . 2001;  96 1631-1634
    PubMedGoogle Scholar
  • 128 Caldwell S H. Efficacy and safety of troglitazone for lipodystrophy syndromes.  Ann Intern Med . 2001;  134 1008
    PubMedGoogle Scholar
  • 129 Funk C, Ponelle C, Scheuermann G, Pantze M. Cholestatic potential of troglitazone as a possible factor contributing to troglitazone-induced hepatotoxicity: in vivo and in vitro interaction at the canalicular bile salt export pump (Bsep) in the rat.  Mol Pharmacol . 2001;  59 627-635
    PubMedGoogle Scholar
  • 130 Shibuya A, Watanabe M, Yoshikuni F. An autopsy case of troglitazone-induced fulminant hepatitis.  Diabetes Care . 1998;  21 2140-2143
    CrossrefPubMedGoogle Scholar
  • 131 Rubin C J, Schneider R L. Pioglitazone liver enzyme profile is similar to placebo in U.S. controlled clinical trials.  Diabetes . 2000;  49(Suppl 1) A123
    PubMedGoogle Scholar
  • 132 Lebovitz H E, Salzman A. Rosiglitazone liver safety update.  Diabetes . 2000;  49(Suppl 1) A39
    PubMedGoogle Scholar
  • 133 Forman L M, Simmons D A, Diamond R H. Hepatic failure in a patient taking rosiglitazone.  Ann Intern Med . 2000;  132 118-121
    PubMedGoogle Scholar
  • 134 Al-Salman J, Arjomand H, Kemp D G, Mittal M. Hepatocellular injury in a patient receiving rosiglitazone. A case report.  Ann Intern Med . 2000;  132 121-124
    PubMedGoogle Scholar
  • 135 Freid J, Everitt D, Boscia J. Rosiglitazone and hepatic failure (letter).  Ann Intern Med . 2000;  132 164
    PubMedGoogle Scholar
  • 136 Maeda K. Hepatocellular injury in a patient receiving pioglitazone (letter).  Ann Intern Med . 2001;  135 306
    PubMedGoogle Scholar
  • 137 Hachey D M, O'Neil M P, Force R W. Isolated elevation of alkaline phosphatase level associated with rosiglitazone (letter).  Ann Intern Med . 2000;  133 752
    PubMedGoogle Scholar
  • 138 Lenhard M J, Funk W B. Failure to develop hepatic injury from rosiglitazone in a patient with a history of troglitazone-induced hepatitis.  Diabetes Care . 2001;  24 168-169
    PubMedGoogle Scholar
  • 139 Tawata M, Ikeda M, Kodama Y. A type 2 diabetic patient with liver dysfunction due to human insulin.  Diabetes Res Clin Pract . 2000;  49 17-21
    CrossrefPubMedGoogle Scholar
  • 140 Tolman K G. Defining patient risks from expanded preventive therapies.  Am J Cardiol . 2000;  85 15E-19E
    CrossrefPubMedGoogle Scholar
  • 141 Farmer J A, Torre-Amione G. Comparative tolerability of the HMG-CoA reductase inhibitors.  Drug Saf . 2000;  23 197-213
    PubMedGoogle Scholar
  • 142 Ballare M, Xampanini M, Airoldi G. Hepatotoxicity of hydroxy-methylglutaryl-coenzyme A reductase inhibitors.  Minerva Gastroenterol Dietol . 1992;  38 41-44
    PubMedGoogle Scholar
  • 143 Nakad A, Bataille L, Hamoir V. Atorvastatin-induced acute hepatitis with absence of cross-toxicity with simvastatin.  Lancet . 1999;  353 1763-1764
    PubMedGoogle Scholar
  • 144 Wierzbicki A S, Crook M A. Cholestatic liver dysfunction.  Lancet . 1999;  354 954
    CrossrefPubMedGoogle Scholar
  • 145 Grimbert S, Pessayre D, Degott C, Benhamou J P. Acute hepatitis induced by HMG-CoA reductase inhibitor, lovastatin.  Dig Dis Sci . 1994;  39 2032-2033
    CrossrefPubMedGoogle Scholar
  • 146 Hartleb M, Rymarczyk G, Januszewski K. Acute cholestatic hepatitis associated with pravastatin.  Am J Gastroenterol . 1999;  94 1388-1390
    CrossrefPubMedGoogle Scholar
  • 147 Huchzermeyer H, Munzenmaier R. Lovastatin-induced acute cholestatic hepatitis.  Dtsch Med Wochenschr . 1995;  120 252-256
    Article in Thieme ConnectPubMedGoogle Scholar
  • 148 Gascon A, Zabala S, Iglesias E. Acute cholestasis during long-term treatment with fluvastatin in a nephrotic patient.  Nephrol Dial Transplant . 1999;  14 1038
    PubMedGoogle Scholar
  • 149 Athyros V G, Papageorgiou A A, Hatzikonstandinou H A. Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia.  Am J Cardiol . 1997;  80 608-613
    CrossrefPubMedGoogle Scholar
  • 150 Punthakee Z, Scully L J, Guindi M M, Ooi T C. Liver fibrosis attributed to lipid lowering medications: two cases.  J Intern Med . 2001;  250 249-254
    CrossrefPubMedGoogle Scholar
  • 151 Ganne-Carrie N, de Leusse A, Guettier C. Autoimmune hepatitis induced by fibrates.  Gastroenterol Clin Biol . 1998;  22 525-529
    PubMedGoogle Scholar
  • 152 Lepicard A, Mallat A, Zafrani E S, Dhumeaux D. Chronic lesion of the interlobular bile ducts induced by fenofibrate.  Gastroenterol Clin Biol . 1994;  18 1033-1035
    PubMedGoogle Scholar
  • 153 Chatrenet P, Regimbeau C, Ramain J P. Chronic active cirrhogenic hepatitis induced by fenofibrate.  Gastroenterol Clin Biol . 1993;  17 612-613
    PubMedGoogle Scholar
  • 154 Lelouch S, Pelletier G, Sinico M. Fenofibrate-induced acute hepatitis with pseudo-cholangitis.  Gastroenterol Clin Biol . 1992;  16 597-599
    PubMedGoogle Scholar
  • 155 Abookire S A, Karson A S, Fiskio J, Bates D W. Use and monitoring of ``statin'' lipid-lowering drugs compared with guidelines.  Arch Intern Med . 2001;  161 53-58
    CrossrefPubMedGoogle Scholar
  • 156 Vittorio C, Muglia J. Anticonvulsant hypersensitivity syndrome.  Arch Intern Med . 1995;  155 2285-2290
    CrossrefPubMedGoogle Scholar
  • 157 Knowles S R, Uetrecht J, Shear N H. Idiosyncratic drug reactions: the reactive metabolite syndromes.  Lancet . 2000;  356 1587-1591
    CrossrefPubMedGoogle Scholar
  • 158 Schlienger R, Knowles S, Shear N. Lamotrigine-associated anticonvulsant hypersensitivity syndrome.  Neurology . 1998;  51 1172-1175
    PubMedGoogle Scholar
  • 159 Bryant 3rd E A, Dreifuss F E. Valproic acid hepatic fatalities. III. U.S. experience since 1986.  Neurology . 1996;  46 465-469
    PubMedGoogle Scholar
  • 160 Krahenbuhl S, Brandner S, Kleinle S. Mitochondrial diseases represent a risk factor for valproate-induced fulminant liver failure.  Liver . 2000;  20 346-348
    PubMedGoogle Scholar
  • 161 Konig S A, Schenk M, Sick C. Fatal liver failure associated with valproate therapy in a patient with Friedreich's disease: review of valproate hepatotoxicity in adults.  Epilepsia . 1999;  40 1036-1040
    CrossrefPubMedGoogle Scholar
  • 162 Schwabe M J, Dobyns W B, Burke B, Armstrong D L. Valproate-induced liver failure in one of two siblings with Alpers disease.  Pediatr Neurol . 1997;  16 337-343
    CrossrefPubMedGoogle Scholar
  • 163 Njolstad P R, Skjeldal O H, Agsteribbe E. Medium chain acyl-CoA dehydrogenase deficiency and fatal valproate toxicity.  Pediatr Neurol . 1997;  16 160-162
    CrossrefPubMedGoogle Scholar
  • 164 Raskind J Y, El-Chaar G M. The role of carnitine supplementation during valproic acid therapy.  Ann Pharmacother . 2000;  34 630-638
    CrossrefPubMedGoogle Scholar
  • 165 Coulter D L. Carnitine, valproate, and toxicity.  J Child Neurol . 1991;  6 7-14
    PubMedGoogle Scholar
  • 166 Bohan T P, Helton E, McDonald I. Effect of L-carnitine treatment for valproate-induced hepatotoxicity.  Neurology . 2001;  56 1405-1409
    CrossrefPubMedGoogle Scholar
  • 167 Kayihan N, Nennesomo I, Ericzon B G, Nemeth A. Fatal deterioration of neurological disease after orthotopic liver transplantation for valproic acid-induced liver damage.  Pediatr Transplant . 2000;  4 211-214
    CrossrefPubMedGoogle Scholar
  • 168 Thomson M A, Lynch S, Strong R. Orthotopic liver transplantation with poor neurologic outcome in valproate-associated liver failure: a need for critical risk-benefit appraisal in the use of valproate.  Transplant Proc . 2000;  32 200-203
    CrossrefPubMedGoogle Scholar
  • 169 Makin A J, Fitt S, Williams R, Duncan J S. Fulminant hepatic failure induced by lamotrigine.  BMJ . 1995;  311 292
    PubMedGoogle Scholar
  • 170 Sauve G, Bresson-Hadni S, Prost P. Acute hepatitis after lamotrigine administration.  Dig Dis Sci . 2000;  45 1874-1877
    CrossrefPubMedGoogle Scholar
  • 171 Arnon R, DeVivo D, Defelice A R, Kazlow P G. Acute hepatic failure in a child treated with lamotrigine.  Pediatr Neurol . 1998;  18 251-252
    CrossrefPubMedGoogle Scholar
  • 172 Fayad M, Choueiri R, Mikati M. Potential hepatotoxicity of lamotrigine.  Pediatr Neurol . 2000;  22 49-52
    CrossrefPubMedGoogle Scholar
  • 173 Bjoro K, Gjerstad L, Bentdal O. Topiramate and fulminant liver failure.  Lancet . 1998;  352 1119
    PubMedGoogle Scholar
  • 174 Doan R J, Clendenning M. Topiramate and hepatotoxicity.  Can J Psychiatry . 2000;  45 937-938
    PubMedGoogle Scholar
  • 175 O'Neil M G, Perdun C S, Wilson M B. Felbamate-associated fatal acute hepatic necrosis.  Neurology . 1996;  46 1457-1459
    PubMedGoogle Scholar
  • 176 Pellock J M. Felbamate.  Epilepsia . 1999;  40(Suppl 5) S57-S62
    PubMedGoogle Scholar
  • 177 Thompson C D, Kinter M T, Macdonald T L. Synthesis and in vitro reactivity of 3-carbamoyl-2-phenylpropionaldehyde and 2-phenylpropenal: putative reactive metabolites of felbamate.  Chem Res Toxicol . 1996;  9 1225-1229
    CrossrefPubMedGoogle Scholar
  • 178 Ishak K G, Irey N S. Hepatic injury associated with the phenothiazines. Clinicopathologic and follow-up study of 36 patients.  Arch Pathol . 1972;  93 283-304
    PubMedGoogle Scholar
  • 179 Dincsoy H P, Saelinger D A. Haloperidol-induced chronic cholestatic liver disease.  Gastroenterology . 1982;  83 694-700
    PubMedGoogle Scholar
  • 180 Lok A S, Ng I O. Prochlorperazine-induced chronic cholestasis.  J Hepatol . 1988;  6 369-373
    CrossrefPubMedGoogle Scholar
  • 181 Villari D, Rubino F, Corica F. Bile ductopenia following therapy with sulpiride.  Virchows Arch . 1995;  427 223-226
    PubMedGoogle Scholar
  • 182 Macfarlane B, Davies S, Mannan K. Fatal acute fulminant liver failure due to clozapine: a case report and review of clozapine-induced hepatotoxicity.  Gastroenterology . 1997;  112 1707-1709
    PubMedGoogle Scholar
  • 183 Krebs S, Dormann H, Muth-Selbach U. Risperidone-induced cholestatic hepatitis.  Eur J Gastroenterol Hepatol . 2001;  13 67-69
    CrossrefPubMedGoogle Scholar
  • 184 Cadario B. Olanzapine (Zyprexa℗): suspected serious reactions.  CMAJ . 2000;  163 85-86
    PubMedGoogle Scholar
  • 185 Habersetzer F, Larrey D, Babany G. Clotiazepam-induced acute hepatitis.  J Hepatol . 1989;  9 256-259
    PubMedGoogle Scholar
  • 186 Andrade R J, Lucena M I, Aguilar J. Chronic liver injury related to use of bentazepam.  Dig Dis Sci . 2000;  45 1400-1404
    CrossrefPubMedGoogle Scholar
  • 187 Anderson B N, Henrikson I R. Jaundice and eosinophilia associated with amitriptyline.  J Clin Psychiatry . 1978;  39 730-731
    PubMedGoogle Scholar
  • 188 Horst D A, Grace N D, LeCompte P M. Prolonged cholestasis and progressive hepatic fibrosis following imipramine therapy.  Gastroenterology . 1980;  79 550-554
    PubMedGoogle Scholar
  • 189 Cooper G L. The safety of fluoxetine-an update.  Br J Psychiatry . 1988;  3 77-86
    PubMedGoogle Scholar
  • 190 Cai Q, Benson M A, Talbot T J. Acute hepatitis due to fluoxetine therapy.  Mayo Clin Proc . 1999;  74 692-694
    PubMedGoogle Scholar
  • 191 Friedenberg F K, Rothstein K D. Hepatitis secondary to fluoxetine treatment (letter).  Am J Psychiatry . 1996;  153 580
    PubMedGoogle Scholar
  • 192 Capella D, Bruguera M, Figueras A, Laporte J. Fluoxetine-induced hepatitis: why is postmarketing surveillance needed?.  Eur J Clin Pharmacol . 1999;  55 545-546
    CrossrefPubMedGoogle Scholar
  • 193 Johnston D E, Wheeler D E. Chronic hepatitis related to use of fluoxetine.  Am J Gastroenterol . 1997;  92 1225-1226
    PubMedGoogle Scholar
  • 194 Benbow S J, Gill G. Paroxetine and hepatotoxicity.  BMJ . 1997;  314 1387
    PubMedGoogle Scholar
  • 195 Helmchen C, Boerner R J, Meyendorf R, Hegerl U. Reversible hepatotoxicity of paroxetine in a patient with major depression.  Pharmacopsychiatry . 1996;  29 223-226
    PubMedGoogle Scholar
  • 196 Odeh M, Misselevech I, Boss J H, Oliven A. Severe hepatotoxicity with jaundice associated with paroxetine.  Am J Gastroenterol . 2001;  96 2494-2496
    CrossrefPubMedGoogle Scholar
  • 197 Lucena M I, Andrade R J, Gomez-Outes A. Acute liver failure after treatment with nefazodone.  Dig Dis Sci . 1999;  44 2577-2579
    CrossrefPubMedGoogle Scholar
  • 198 Aranda-Michel J, Koehler A, Bejarano P A. Nefazodone-induced liver failure: report of three cases.  Ann Intern Med . 1999;  130 285-288
    PubMedGoogle Scholar
  • 199 Schirren C A, Baretton G. Nefazodone-induced acute liver failure.  Am J Gastroenterol . 2000;  95 1596-1597
    PubMedGoogle Scholar
  • 200 Eloubeidi M A, Gaede J T, Swaim M W. Reversible nefazodone-induced liver failure.  Dig Dis Sci . 2000;  45 1036-1038
    CrossrefPubMedGoogle Scholar
  • 201 Sheikh K H, Nies A S. Trazodone and intrahepatic cholestasis.  Ann Intern Med . 1983;  99 572
    PubMedGoogle Scholar
  • 202 Beck P L, Bridges R J, Demetrick D J. Chronic active hepatitis with trazodone therapy.  Ann Intern Med . 1993;  118 791-792
    PubMedGoogle Scholar
  • 203 Fernandes N F, Martin R R, Schenker S. Trazodone-induced hepatotoxicity: a case report with comments on drug-induced hepatotoxicity.  Am J Gastroenterol . 2000;  95 532-535
    PubMedGoogle Scholar
  • 204 Kim K Y, Hwang W, Narendran R. Acute liver damage possibly related to sertraline and venlafaxine ingestion.  Ann Pharmacother . 1999;  33 381-382
    PubMedGoogle Scholar
  • 205 Hull M, Jones R, Bendall M. Fatal hepatic necrosis associated with trazodone and neuroleptic drugs.  BMJ . 1994;  309 378
    PubMedGoogle Scholar
      >